Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
The latest from Dr. Falk Pharma
Welcome to our Newsroom, providing you with the latest news, press releases, clinical trial announcements, events, and more from Dr. Falk Pharma.
Follow us on LinkedIn!
Elena in Germany
...the final chapter of her journey following the footsteps of our founder.
Elena in Portugal
... where Prof. Dr. Fernando J. Magro Dias told her a lot about her grandfather.
Dr. Falk Pharma acquires Kynos Therapeutics
...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
Elena in Freiburg, Germany
Stop no. 2: Elena is following the footsteps of her grandpa and talks to Falk employees in Germany
Following the footsteps of our founder
Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.
Dosing of the First United States Patient
...and expansion of the Phase 2b Study of Naronapride in Gastroparesis
New Addition to the Management Board
The new Technical Operations business unit will be headed up by Dr. Andreas Rascher
Corum – Place To Share
Read about yesterday's groundbreaking ceremony for the building in which we will be working in as of 2026.
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
Advancing the development of naronapride...
...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication
Eating should be a pleasure
What does it feel like to eat when you know that each bite will hurt when swallowing?
EoE Week 2023
We support this year’s EoE Week in order to help raise awareness for eosinophilic esophagitis.
Management change at Dr. Falk Pharma GmbH
Kai Pinkernell takes over as Managing Director Science & Innovation.
Rare Disease Day
As the experts in digestive and metabolic medicine, our focus is also on rare diseases.
Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated
Collaboration and Licensing Agreement with Takeda and Zedira
To Develop First-in-Class Celiac Disease Therapy
NAFLD: Phase 2a proof of concept study of ZED1227
Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
International Liver Congress™ in London
We are proud to be a sponsor and look forward to seeing you in person on our booth no. 69 or online, 22-26 June 2022!
Digestive Disease Week® 2022
We look forward to 2 exciting presentations on day 4 of this year’s DDW!
Have difficulty swallowing food?
Difficulty swallowing and pain while eating may be warning signs of eosinophilic esophagitis (EoE). The first EoE Day will be held on May 22, 2022.
Response to the Ukraine crisis
Dr. Falk Pharma supports APOTHEKER HELFEN e.V.
Future starts here
Plans for the future Falk Campus in Freiburg-Nord finalized.
Together we advance PR600
Investigational New Drug Application for PR600 expected in 3Q 2022.